Search Results

Tagging GPCRs expressed in cellular compartments such as the nucleus or endosomes presents several pharmaceutical Overall, the pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments Pharmaceuticals (Basel, Switzerland), 14(5), 439. https://doi.org/10.3390/ph14050439 Chen, K.

expansion as the leading GPCR immuno-oncology company Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer Rhythm Pharmaceuticals and LG Chem Life Sciences

"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

📰 GPCR Weekly News, July 22 to 28, 2024 In the fast-paced world of pharmaceuticals and drug discovery

Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics Appoints Dieter Weinand, Former CEO Of Bayer Pharmaceuticals Wainwright 25th Annual Global Investment Conference X4 Pharmaceuticals to Participate in the Morgan Stanley

Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals

Act fast to secure your place in our upcoming course ! £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform GPCR Safety Panels Launched Crinetics Pharmaceuticals

Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

inactive conformation using molecular dynamic simulations "The δ-opioid receptor (DOR) is a critical pharmaceutical

Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

However, AlphaFold3 faces challenges with synthetic ligands, which are central to pharmaceutical development

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals Explore Dr.

given the Society’s conference will be held in Perth next year, in collaboration with the Australasian Pharmaceutical

Advances in GPCRs: Structure, Mechanisms, Disease, and Pharmacology Industry News Monash University pharmaceutical Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology Crinetics Pharmaceuticals

2011, she had established her own group within the Drug Discovery Biology theme at Monash Institute of Pharmaceutical

Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Crinetics Pharmaceuticals Update Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Crinetics Pharmaceuticals

In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design

Slow-rising and fast-falling dopaminergic dynamics jointly adjust negative prediction error in the ventral Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics Pharmaceuticals

Expertise in Oncology Octant Bio will be at the Goldman Sachs Global Healthcare Conference Crinetics Pharmaceuticals

But at Monash Institute of Pharmaceutical Sciences, a different idea took root: what if collaboration

Poon to Board of Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing

By identifying key β2AR residues that influence efficacy and potency, pharmaceutical researchers can

She entered undergrad set on becoming a pharmacist. kind of had an identity crisis because I think I realized in that moment that I didn't want to be a pharmacist

Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

develop new therapies for people living with obesity, diabetes and other serious metabolic diseases X4 Pharmaceuticals

Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Crinetics Pharmaceuticals

exclusively to our Premium Members this week: Industry insights:  Discover the latest strategic moves in the pharmaceutical

all symptoms of schizophrenia Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals

spinning GPR68 small molecules into GIO New treatments being developed for schizophrenia Crinetics Pharmaceuticals